| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
AB Stock Overview
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines.
AB Science Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.30 |
| 52 Week High | €16.68 |
| 52 Week Low | €6.95 |
| Beta | 0.88 |
| 1 Month Change | -11.51% |
| 3 Month Change | -6.53% |
| 1 Year Change | -37.88% |
| 3 Year Change | 133.96% |
| 5 Year Change | -5.10% |
| Change since IPO | -26.66% |
Recent News & Updates
Shareholder Returns
| AB | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | 2.1% | 3.5% | -1.5% |
| 1Y | -37.9% | 17.8% | -18.8% |
Return vs Industry: AB underperformed the French Pharmaceuticals industry which returned 17.8% over the past year.
Return vs Market: AB underperformed the French Market which returned -18.8% over the past year.
Price Volatility
| AB volatility | |
|---|---|
| AB Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in FR Market | 10.2% |
| 10% least volatile stocks in FR Market | 3.5% |
Stable Share Price: AB is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 98 | Alain Moussy | https://www.ab-science.com |
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19.
AB Science Fundamentals Summary
| AB fundamental statistics | |
|---|---|
| Market Cap | €439.54m |
| Earnings (TTM) | -€14.46m |
| Revenue (TTM) | €1.61m |
271.2x
P/S Ratio-30.1x
P/E RatioIs AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AB income statement (TTM) | |
|---|---|
| Revenue | €1.61m |
| Cost of Revenue | €111.00k |
| Gross Profit | €1.50m |
| Other Expenses | €15.96m |
| Earnings | -€14.46m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 30, 2022
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 93.09% |
| Net Profit Margin | -900.00% |
| Debt/Equity Ratio | -58.9% |
How did AB perform over the long term?
See historical performance and comparisonValuation
Is AB Science undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
In this section, we usually try to help investors determine whether AB Science is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AB Science has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Future Growth
How is AB Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
8.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AB Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has AB Science performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
15.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AB is currently unprofitable.
Growing Profit Margin: AB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AB is unprofitable, but has reduced losses over the past 5 years at a rate of 15.7% per year.
Accelerating Growth: Unable to compare AB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: AB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Financial Health
How is AB Science's financial position?
Financial Health Score
2/6Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AB has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AB has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AB is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.
Dividend
What is AB Science current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AB has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
0.9yrs
Average board tenure
CEO
Alain Moussy
20.83yrs
Tenure
€622,000
Compensation
Mr. Alain Moussy, MBA is a Co-Founder of AB Science S.A. and has been its Chief Executive Officer since July 2001 and Managing Director. Mr. Moussy serves as Chairman since July 11, 2001 and serves as its...
CEO Compensation Analysis
Compensation vs Market: Alain's total compensation ($USD667.38K) is above average for companies of similar size in the French market ($USD462.48K).
Compensation vs Earnings: Alain's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: AB's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
AB Science S.A.'s employee growth, exchange listings and data sources
Key Information
- Name: AB Science S.A.
- Ticker: AB
- Exchange: ENXTPA
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €439.542m
- Shares outstanding: 46.86m
- Website: https://www.ab-science.com
Number of Employees
Location
- AB Science S.A.
- 3, Avenue George V
- Paris
- Ile-de-France
- 75008
- France
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/24 00:00 |
| End of Day Share Price | 2022/05/24 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.